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Background:  Fibroblast growth factor 21 (FGF21) was originally identified as a paroxysm proliferator activated receptor-α tar-
get gene product and is a hormone involved in metabolic regulation. The purpose of this study was to investigate the diurnal 
variation of serum FGF21 concentration in obese and non-obese healthy volunteers.
Methods:  Blood samples were collected from five non-obese (body mass index [BMI] ≤23 kg/m
2) and five obese (BMI ≥25 kg/
m
2) healthy young men every 30 to 60 minutes over 24 hours. Serum FGF21 concentrations were determined by radioimmuno-
assay. Anthropometric parameters, glucose, free fatty acid, insulin, leptin, and cortisol concentrations were also measured. 
Results:  The serum FGF21 concentrations displayed various individual oscillation patterns. The oscillation frequency ranged 
between 6 and 12 times per day. The average duration of oscillation was 2.52 hours (range, 1.9 to 3.0 hours). The peaks and troughs 
of FGF21 oscillation showed no circadian rhythm. However, the oscillation frequency had a diurnal variation and was lower dur-
ing the light-off period than during the light-on period (2.4 vs. 7.3 times, P<0.001). There was no difference in the total frequen-
cy or duration of oscillations between non-obese and obese subjects, but obese individuals had increased numbers of larger os-
cillations (amplitude ≥0.19 ng/mL).
Conclusion:  Various oscillation patterns in serum FGF21 concentration were observed, and reduced oscillation frequencies were 
seen during sleep. The oscillation patterns of serum FGF21 concentration suggest that FGF21 may be secreted into systemic cir-
culation in a pulsatile manner. Obesity appeared to affect the amplitude of oscillations of serum FGF21.
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INTRODUCTION
Fibroblast growth factor-21 (FGF21) is a 210-amino acid pep-
tide belonging to the FGF19 family [1]. In rodents, FGF21 
mRNA is widely expressed in peripheral metabolic tissues, 
such as the liver, pancreas, skeletal muscle, and white adipose 
tissue [1-3]. FGF21 protein also has been detected in plasma 
[4], which suggests that it is secreted into systemic circulation 
and may act like a hormone. Indeed, FGF21 binds to FGF re-
ceptors and its coreceptor β-klotho on plasma membranes 
[5,6], activating Akt signaling pathways [7].
  Prolonged fasting was found to increase hepatic FGF21 
transcription in rodents, and this increased transcription was 
mediated by peroxisome proliferator activated receptor-α 
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(PPARα) [8]. Elevated FGF21 levels during fasting appear to 
be important for metabolic adaptation to a low energy state by 
inducing increased ketogenesis, lipolysis, and torpor-like be-
havior [9,10]. On the other hand, accumulated data demon-
strate the beneficial effects of FGF21 on glucose and lipid me-
tabolism [11,12]. FGF21-overexpressing mice were resistant 
to the development of diet-induced obesity [13]. Treatment of 
adipocytes with FGF21 stimulated glucose uptake in an insulin-
independent manner. Moreover, FGF21 treatment in a mouse 
model of diabetes mellitus improved insulin resistance and 
lowered plasma glucose and triglyceride concentrations [13]. 
Similarly, the treatment of diabetic monkeys with FGF21 cor-
rected insulin resistance and improved β-cell function. These 
results indicate that FGF21 may be a promising target in the 
treatment of diabetes mellitus [12]. 
  In humans, morning fasting serum FGF21 concentrations 
were not significantly altered by short-term fasting but were 
increased by treatment with the PPARα ligand fenofibrate 
[14]. Circulating FGF21 concentrations also were elevated in 
patients with type 2 diabetes compared to non-diabetic indi-
viduals and were negatively correlated with fasting blood glu-
cose concentration [15]. Moreover, fasting serum FGF21 levels 
were positively associated with parameters of obesity, such as 
body mass index (BMI) and waist to hip ratio (WHR) [16,17], 
although another study reported no such correlation [14]. 
However, the physiological roles of FGF21 in human metabo-
lism remain obscure. 
  Serum concentrations of hormones engaged in metabolic 
regulation often display unique diurnal patterns, from which 
we can infer their physiological roles. For example, serum in-
sulin concentrations are elevated after meal intake but sup-
pressed during fasting [18]. This diurnal pattern of insulin is 
indicative of its critical role in postprandial glucose disposal. 
In contrast, elevated plasma glucagon and cortisol concentra-
tions during fasting suggest that these hormones are impor-
tant formetabolic adaptation to fasting [19]. Circulating con-
centrations of the appetite-stimulating hormone ghrelin also 
are increased just before food ingestion [20], a finding that is 
compatible with its role as a meal initiator.
  Aberrant circadian rhythms are closely associated with 
metabolic abnormalities and obesity [21,22]. Hepatic FGF21 
expression was recently shown to be regulated by clock tran-
scriptional factors, such as retinoic acid receptor-related or-
phan receptor-α (RORα) and Rev-Erbα [23,24]. A previous 
study investigated serum FGF21 concentrations over 24 hours 
in five non-obese subjects and found that serum FGF21 levels 
oscillated but were stable throughout the day, without definite 
diurnal variations or meal-related changes [14]. That study, 
however, did not investigate the 24 hour profile of serum FGF21 
concentrations in obese subjects. Therefore, in the present 
study, we compared serum FGF21 concentrations over 24 
hours between obese and non-obese healthy volunteers.
METHODS
Study subjects
Five non-obese and five obese healthy male volunteers were 
recruited through website advertisements, as described previ-
ously [25]. At the first visit, anthropometric parameters were 
measured before breakfast, with the subjects wearing light 
clothing and no shoes. The BMI of each subject was calculated 
as weight/height
2 (kg/m
2). Non-obese individuals were defined 
as having a BMI of 18.5 to 22.9 kg/m
2, and obese individuals 
were defined as having a BMI of ≥25 kg/m
2, in accordance 
with the definition for Asian adults proposed by the Western 
Pacific Region of the World Health Organization (WPRO) [26]. 
Waist circumference was measured to the nearest 0.1 cm at the 
level of the greatest frontal extension of the abdomen between 
the bottom of the rib cage and the top of the iliac crest; hip cir-
cumference was measured at the level of the widest part of the 
hips. Blood pressure was measured from the right arm after a 
20 minute rest. Metabolic disorders were screened by collect-
ing blood samples from all subjects after an overnight (10 
hours) fast. Plasma and serum were immediately separated 
and stored at -70°C until measurement. 
  Inclusion criteria were: 1) age of 18 to 60 years; 2) BMI of 17 
to 23 kg/m
2 for the non-obese group and 25 to 40 kg/m
2 for 
the obese group; and 3) no clinical evidence of other medical 
conditions, such as hypertension; diabetes mellitus; pulmo-
nary, cardiovascular, liver and renal diseases; or alcohol or 
drug abuse. Exclusion criteria included: 1) a ≥5% weight loss 
over at previous 3 months; 2) current medication, including 
herbal, nutritional, or vitamin supplements; 3) psychiatric ill-
ness; 4) gastrointestinal surgery; 5) smoking; 6) heavy alcohol 
consumption (>2 drinks per day); and 7) intensive exercise 
(≥30 minutes, ≥3 times per week). 
  This study was approved by the Human Research Ethics 
Committee of Asan Medical Center, Seoul, Korea. All proce-
dures were conducted in accordance with the Declaration of 
Helsinki. Informed consent was obtained from all subjects.31
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Study design and blood sampling 
Before admission, eating behaviors and diet patterns were 
evaluated by a dietician by recording the diet for 3 days. The 
dietician instructed the subjects to consume a diet composed 
of 60% carbohydrate, 25% fat, and 15% protein to maintain 
current body weight for 1 week before participation in the 
study. At the end of the one-week diet control period, all sub-
jects were admitted to the Asan Clinical Research Center at 
17:00 hour 1 day before study initiation and were provided 
with dinner. After an overnight fast, blood sampling began at 
07:00 hour the next morning. Blood samples were obtained 
every 30 minute from 07:00 to 21:00 hour and then every hour 
until 07:00 hour the next morning. During a study day, a meal 
was provided at 08:00, 12:30, and 18:00 hour, without snacks. 
The subjects spent their time in bed, except during waste elim-
ination. Lights were off from 22:00 to 06:00 hour.
Assays
Blood samples were collected in serum-separating tubes con-
taining aprotinin (250 kallikrein inhibitor units; Sigma-Aldrich, 
Seoul, Korea). Serum FGF21 concentrations were assayed with 
a radioimmunoassay kit (Phoenix Europe, Karlsruhe, Germa-
ny) in accordance with the manufacturer’s instructions. The 
lower and upper detection limits of FGF21 were 0.23 and 30 
ng/mL, respectively. Fasting glucose, total cholesterol, triglyc-
erides, and high density lipoprotein cholesterol were measured 
enzymatically with an auto-analyzer (Hitachi E170; Hitachi 
Ltd., Tokyo, Japan). Serum-free fatty acid (FFA) was measured 
by enzyme immunoassay with Viva-E (Dade Behring Inc., 
Deerfield, IL, USA). Commercial radioimmunoassay (RIA) 
kits were used to measure levels of insulin, leptin (Linco Re-
search, St. Charles, MO, USA) and cortisol (Siemens Health-
care Diagnostics, Los Angeles, CA, USA). 
Statistical analysis
Data are presented as the mean±standard error of the mean 
(SEM). The 24 hour integrated area under the curve (AUC) 
was calculated by the trapezoid method. The oscillatory pat-
terns of serum FGF21 in the non-obese and obese groups were 
compared using the Mann-Whitney U test. Spearman’s corre-
lation coefficient analysis was performed to determine the fac-
tors associated with serum FGF21 levels. SPSS version 14.0 
software (SPSS Inc., Chicago, IL, USA) was used for statistical 
analysis. A P value of less than 0.05 was considered statistically 
significant.
RESULTS
Subject characteristics 
The average age (mean±SEM) of the subjects was 23±1 years; 
their baseline anthropometric and biochemical findings were 
presented in our previous paper [25]. The average BMIs of the 
non-obese and obese groups were 21.9±0.6 and 29.8±1.4 kg/
m
2, respectively, and the average waist circumferences were 
80.4±2.1 cm and 98.4±2.8 cm, respectively. Compared to the 
non-obese group, the fasting plasma leptin concentrations 
were significantly higher in the obese group; the fasting insu-
lin, glucose, FFA, and low density lipoprotein cholesterol con-
centrations tended to be higher in the obese group (data not 
shown). 
24 hour profiles of serum FGF21 concentration 
Among all subjects, the average fasting morning serum FGF21 
concentration was 0.58±0.01 ng/mL (range, 0.44 to 0.94 ng/
mL). The serum FGF21 concentrations showed oscillating 
patterns over 24 hours, with a frequency of oscillation of 6 to 
12 times per day (Fig. 1). The average FGF21 excursion value 
between peak and trough was 0.19±0.01 ng/mL (range, 0.13 
to 0.27 ng/mL). The average time interval between peaks was 
2.4 hours, with large inter- and intra-individual variations. Al-
though the peaks and troughs of serum FGF21 oscillations did 
not show a definite circadian rhythm (Fig. 1), the oscillation 
frequencies were significantly reduced (2.4 vs. 7.3 times, P<
0.001) and the average duration of oscillations was increased 
(3.5 vs. 1.8 hours, P<0.001) in the light-off period compared 
Fig. 1. The 24 hour profiles of serum fibroblast growth factor 
21 (FGF21) and other metabolite concentrations in 10 healthy 
male volunteers. The subjects consumed breakfast (B), lunch 
(L), and dinner (D) at the times indicated. The shaded area rep-
resents the lights-off period. 
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Fig. 2. Individual diurnal pattern of serum fibroblast growth factor 21 (FGF21). Note the inter-individual variation and the het-
erogeneity of the oscillation patterns. Serum FGF21 profiles of non-obese (L) subjects are shown in the left panels, whereas those 
of obese (O) subjects are shown in the right panels. B, breakfast; L, lunch; D, dinner.
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to the light-on period.
  The individual profiles of serum FGF21 levels are presented 
in Fig. 2. There were larger inter-individual variations in diur-
nal rhythms and oscillation patterns of circulating FGF21. The 
peak serum FGF21 concentrations declined with daily progres-
sion in non-obese subject #2 (L2) and obese subject #1 (O1), 
but none of the other subjects showed a definite diurnal pat-
tern. L1, L5, O2, and O5 showed smaller and more frequent 
oscillations, whereas L3, L4, O1, O3, and O4 had larger and 
less frequent oscillations (Fig. 2).
  When we compared serum FGF21 concentrations in the 
obese and non-obese groups, we found no significant differ-
ence in the mean, maximum, minimum, or AUC values be-
tween the two groups (Table 1). In addition, the oscillation pa-
rameters, including the total oscillation frequency, duration, 
and excursion values, did not differ between the obese and 
non-obese groups (Table 1). 
  Because the mean excursion value of serum FGF21 was 
0.19 ng/mL, we defined a large oscillation as an excursion val-
ue ≥0.19 ng/mL and a small oscillation as an excursion value 
<0.19 ng/mL. As shown in Table 1, the frequency of large os-
cillations was greater in the obese than in the non-obese group 
(4.8±0.7 vs. 2.4±0.5 times, P<0.05). 
Correlation of serum FGF21 levels and metabolic 
parameters
We observed a significant correlation between the morning 
fasting levels (average values at 07:00, 07:30, and 08:00 hour) 
and the 24 hour integrated AUC values of serum FGF21 (Fig. 
3). Fig. 4 shows the 24 hour profiles of FFA, glucose, insulin, 
leptin, and cortisol, together with those of FGF21. The correla-
tion coefficient analyses showed that the fasting and 24 hour 
integrated AUC levels of serum FGF21 were not significantly 
associated with other factors, such as fasting blood lipid pro-
files, insulin, leptin, cortisol, glucose, BMI, or WHR (data not 
shown). Notably, the fasting FFA level was significantly corre-
lated with 24 hour AUC values of serum FGF21 (r=0.673, P<
0.05).
DISCUSSION 
The present study reports the 24 hour profiles of circulating 
FGF21 in 10 healthy subjects. Inconsistent with previous re-
port [14], we found oscillating patterns in the serum FGF21 
concentrations. The frequency of oscillation ranged from 6 to 
12 times per day, with an average oscillation duration of about 
2.5 hours. An earlier study [14] missed many oscillations per-
haps because they collected blood samples every 90 minute. 
Although some individuals showed diurnal variations in the 
peak and trough levels of oscillation of serum FGF21, there 
was no consistent circadian pattern. Notably, the oscillation 
frequency was significantly diminished and the oscillation du-
Table 1. Comparison of serum FGF 21 concentrations between 
non-obese and obese subjects
Variable
Non-obese 
(n=5)
Obese 
(n=5)
P value
FGF21, ng/mL
Fasting mean  0.53±0.08 0.65±0.12 0.40
24 hr mean 0.61±0.11 0.50±0.07 0.45
24 hr AUC 14.74±2.41 12.01±1.64 0.38
Minimum 0.36±0.07 0.29±0.04 0.45
Maximum 1.06±0.10 0.93±0.13 0.48
Oscillation
Total frequency 8.60±0.93 9.40±0.86 0.65
Time interval, hr 2.63±0.23 2.43±0.19 0.52
Mean excursion, ng/mL 0.20±0.02 0.19±0.01 0.48
No. of large oscillations  2.40±0.51 4.80±0.68 0.03
a
No. of small oscillations 6.20±0.58 4.82±0.80 0.20
Values are presented as mean±standard error.
FGF21, fibroblast growth factor 21; AUC, area under the curve.
aP<0.05.
Fig. 3. Correlation of average morning fasting concentrations 
of fibroblast growth factor 21 (FGF21) with 24 hour area un-
der the curve (AUC) values. 
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ration was prolonged during sleep; these findings suggest that 
the changes in oscillation frequency may represent diurnal 
variations. 
  In contrast to our findings, two recent papers have demon-
strated a circadian rhythm in serum FGF21 levels. The levels 
reached a nadir in late afternoon and a peak in early morning 
[27,28]. In those studies, the oscillatory patterns of serum 
FGF21 were not clearly analyzed. The reason for the discrep-
ancy in the circadian variations of FGF21 is unclear at present 
but may be due to the differences in the FGF21 assay and study 
subjects used.
  Several papers have investigated the mechanisms regulating 
hepatic FGF21 mRNA expression. Fasting was shown to in-
crease serum FGF21 levels in rodents, which may be mediated 
via PPARα activation [9]. Similarly, the administration of the 
PPARα ligand bezafibrate was found to increase hepatic 
FGF21 mRNA [8]. This effect was only significant when bezaf-
ibrate was administered at the onset of night. As an endoge-
nous ligand of PPARα, FFA may also affect FGF21 production 
or secretion. Yu and colleagues [27] have shown that serum 
FGF21 levels are temporally correlated with serum FFA. They 
also demonstrated that treatment with the linoleate increased 
FGF21 mRNA and protein levels in HepG2 hepatocytes and 
stimulated FGF21 secretion from the cells [29]. Similarly, we 
found that 24 hour AUC values of FGF21 were significantly 
correlated with the fasting FFA levels. 
  FGF21 production is known to be under circadian regula-
tion. Rev-Erbα, an important regulator of circadian rhythm, 
suppresses FGF21 expression by directly binding to the pro-
moter region of the FGF21 gene promoter region [23]. Anoth-
er clock transcriptional factor, RORα, stimulates FGF21 
mRNA and secretion [24]. These findings suggest that FGF21 
production may be controlled in a circadian manner. Howev-
er, the physiological mechanisms responsible for FGF21 secre-
tion from the cells and the oscillatory pattern in serum FGF21 
concentration remain unknown.
Fig. 4. Comparison of the 24 hour profiles of free fatty 
acid (A), glucose (B), insulin (C), cortisol (D), and leptin 
(E) concentrations with serum fibroblast growth factor 
21 (FGF21). B, breakfast; L, lunch; D, dinner.
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  When we compared the circulating FGF21 concentrations 
and oscillation patterns between obese and non-obese sub-
jects, we found no difference between groups in the mean, 
maximum, minimum, or 24 hour integrated AUC values of 
serum FGF21. Interestingly, the number of larger oscillations 
was significantly greater in obese subjects, suggesting that 
obesity may influence the magnitude rather than the frequen-
cy or duration of oscillations. In contrast, Yu et al. [27] found 
that daytime serum FGF21 levels were elevated and a noctur-
nal rise was blunted in obese subjects. 
  Obesity is associated significantly with increased circulating 
FGF21 concentrations in rodents. However, in humans, the 
relationship between circulating FGF21 and BMI (a marker of 
adiposity) remains unclear. For example, one study in 76 healthy 
non-obese subjects found that the serum FGF21 levels did not 
correlate with BMI [14], whereas other studies have demon-
strated a positive correlation between these values [15-17,30]. 
Such discrepancies may be due to differences in the sample 
sizes or subject characteristics or to the relatively large inter-
individual variations of serum FGF21 concentrations. In our 
study, the obese subjects were not severely obese (average BMI 
~30 kg/m
2) and were relatively metabolically healthy and 
young. Because there are certain obese individuals with nor-
mal metabolic profiles and vice versa [14,16], it may be worth-
while to stratify FGF21 concentration not just by BMI but also 
by metabolic profile. Indeed, we found that the subjects with 
higher serum FFA levels had higher FGF21 levels, indepen-
dent of BMI. 
  Our study may be limited by the small number of subjects 
and the short observation period. However, our findings are 
valuable in that they represent the first analysis of the oscilla-
tion patterns of serum FGF21 in non-obese versus obese sub-
jects. 
  In summary, the oscillation frequency of serum FGF21 
concentration had diurnal rhythm, and the magnitude of the 
oscillation was affected by adiposity. These findings suggest 
that the oscillation patterns of serum FGF21 in humans may 
be affected by metabolic conditions. 
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